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Abstract Besides its preventive action on bone resorp-
tion the third generation bisphosphonate zoledronic acid
(ZOL) has been shown to display potent inhibitory action
on the formation of bone metastases of various human
cancers. Recent research also indicates an antitumoral
effect on primary tumors and visceral metastases. Here we
investigate for the first time the effect of ZOL on the
human colon carcinoma cell line HCT-116. ZOL strongly
inhibited the proliferation and soft agar colony formation
of HCT-116 cells and caused a G1 cell cycle arrest in a
population of ZOL treated cells. This cell cycle arrest was
accompanied by an induction of apoptosis via a caspase
dependent mechanism. Activation of Caspases 3, 7, 8 and
9, cleavage of PARP as well as the release of cytochrome C
into the cytosol were detected in HCT-116 cells treated
with low micromolar concentrations of ZOL. The induction
of the mitochondrial pathway of apoptosis was accompa-
nied by a translocation of Bax into the mitochondria, Bid
activation and a decrease of overall Bcl-2 expression. We
also detected a cytosolic increase of apoptosis inducing
factor (AIF), a trigger of caspase-independent apoptosis.
Taken together, our data indicate a potent antitumoral and
apoptosis inducing effect of ZOL on HCT-116 colon car-
cinoma cells.
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Introduction
The use of bisphosphonates for the treatment of degener-
ative bone diseases such as osteoporosis is well established
and generally well tolerated. Due to their inhibitory action
on bone resorbing osteoclasts bisphophonates prevent an
excessive breakdown of bone tissue [1]. Besides its bone
sparing properties, Zoledronic acid (ZOL), a third genera-
tion bisphosphonate, has been shown to exert powerful
antitumoral properties in a variety of human cancers [2]. In
this context ZOL is the current clinical standard for the
prevention of bone metastases of human cancers. ZOL acts
as an inhibitor of farnesyldiphosphate synthase [3],
blocking the biosynthesis of precursors needed for the
prenylation of small gtp-binding proteins, and thus not only
reduces the activity of osteoclasts but also prevents or
slows the progression of certain tumor cells into healthy
bone tissue [4–6]. Besides its well established effect on the
formation of bone metastases, there is promising evidence
of a broader antitumoral activity [7]. Treatment of prostate,
mammary, lung, kidney and skin cancer cell lines with
ZOL resulted in a slowing of tumor cell proliferation, cell
cycle arrest and induction of apoptosis [8]. Furthermore
ZOL reduced the invasive behaviour of breast and prostate
cancer cells which is likely due to alterations in the orga-
nization of the cytoskeleton and a reduced activity of
matrix proteinases [9]. Treatment with ZOL reduces the
formation of bone metastases of various tumor entities and
Lilian Sewing and Florian Steinberg contributed equally to this work.
L. Sewing  H. Schmidt  R. Go¨ke
Clinical Research Unit for Gastrointestinal Endocrinology,
University of Marburg, 35033 Marburg, Germany
F. Steinberg (&)
DKF Rheumatology, University of Bern, Murtenstr. 35,
3010 Bern, Switzerland
e-mail: steinberg@dkf.unibe.ch
123
Apoptosis (2008) 13:782–789
DOI 10.1007/s10495-008-0211-z
significantly reduces bone related complications [10].
These findings led to the FDA approval of ZOL in com-
bination with established antineoplastic drugs for the
treatment of bone metastases of solid cancers [11]. Besides
the established effect on bone metastases, there is prom-
ising evidence from animal models for the efficacy of ZOL
in the treatment of primary tumors and visceral metastases.
In a murine mammary tumor xenograft model ZOL
reduced the formation of liver and lung metastases [12],
while Minodronat slowed primary tumor growth and pro-
longed survival of mice transplanted with melanoma cells
[13]. Similar results were obtained in murine models of
cervical carcinoma, where ZOL reduced angiogenesis and
induced apoptosis of neoplastic epithelial cells [14].
Colon carcinoma is the second most common cancer in
humans with surgical removement of the primary tumor
usually being the best treatment option [15]. Since any
remaining tumor tissue or metastases often resist conven-
tional chemotherapy it is necessary to develop alternative
treatment options. Here we investigate for the first time the
effects of the third generation bisphosphonate ZOL on a
human colon carcinoma cell line, focusing on its effect on
proliferation, cell cycle and apoptosis.
Materials and methods
ZOL was obtained from Sigma (Taufkirchen, Germany),
dissolved in PBS and stored as a 5 mM stock solution at
-20C.
Cell culture
Wildtype, p53 positive HCT-116 cells were obtained from
the ATCC and kept in a standard incubator with a 5% CO2
atmosphere and cultured in McCoy’s 5A medium with
media containing 10% fetal calf serum and 40 lg/ml
gentamicin. Cells were splitted 1:10 every 5 days.
MTT assay
20.000 cells/well were seeded into twelve well plates and
left there to adhere over night. The cells were then incu-
bated for 5 days in the absence and presence of 1 to 50 lM
ZOL. Then 100 ll methylthiazoletetrazolium (5 mg/ml in
PBS) were added and incubation continued for 2 h. After
removal of the medium cells were treated with 200 ll
DMSO for 15 min. The absorbance of supernatants was
determined at 550 nm in a multi well plate reader. The
percentage of viable cells in relation to the untreated
control group was calculated using the formula: (extinction
of treated sample 9 100)/(extinction of control sample).
Soft agar assay
To study anchorage independent growth of HCT-116 cells
treated with ZOL, a colony forming assay in a soft agar
matrix was performed. 20,000 cells in 0.35% agar (Bacto
Agar; Becton Dickinson, Franklin Lakes, NJ) were layered
on top of 1 ml of a solidified 0.6% agar layer in a 35 mm
dish. Into the growth media with 10% FCS either 12.5 lM
or 25 lM of ZOL were added in both layers. After 14 days
of growth colonies above a chosen size on a counting grid
in the microscope were counted as colonies. The number of
colonies in 10 randomly chosen fields of vision was
counted and compared between ZOL treated and control
wells without ZOL in the medium. In order to take pictures
of the colonies 60,000 instead of 20,000 cells were sub-
jected to the same assay and pictures were taken using a 59
objective of a Zeiss Axiovert 10 microscope.
Western blotting
Total proteins were extracted from adherent and detached
cells and protein concentration was determined using a
protein assay from Bio-Rad according to the manufac-
turer’s protocol. Proteins (15 lg) were resolved by SDS/
PAGE (10% for all proteins except cytochrome c, where a
15% gel was used) and electrotransferred onto nitrocellu-
lose membranes (poresize 0.2 lm). Immunodetection was
carried out using antibodies directed against caspase 3
(9662), caspase 7 (9492), caspase 8 (9746), caspase 9
(9502) (all from Cell Signaling Technologies, Beverly,
MA, USA), Bax (N-20), AIF (D-20), Bid (C-20), Bcl-2 (C-
2) and Bcl/xl (L-19) (all from Santa Cruz, Charlottesville,
VA, USA), in 50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
0.1% Tween 20, 5% non-fat dry milk, followed by HRP-
conjugated secondary antibodies. Detection was performed
using an ECL kit (Amersham Bioscience). Cytosolic pro-
tein extracts were prepared by lysing the cells with a
hypoosmotic buffer containing 20 mM Hepes pH 7.5,
10 mM KCL, 1 mM EDTA, 1 mM DTT, 0.5 mM Prote-
asearrest Inhibitor cocktail followed by ultracentrifugation
at 100,000 g for 1 h.
Flow cytometric cell cycle and apoptosis analysis
HCT-116 cells were incubated with 0 to 50 lM ZOL for
72 h. For the cell cycle analysis only adherent cells were
harvested and fixed in ice-cold 70% (v/v) ethanol for 24 h at
4C. For the apoptosis assay adherent as well as detached
cells from the culture supernatant were harvested and
subjected to the same fixation method. After centrifugation
the cell pellet was resuspended in PBS, pH 7.4, containing
1 lg/ml DNase-free RNase, 50 lg/ml propidium iodide and
0.1% glucose. Cells were incubated at room temperature in
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the dark for 4 h, and DNA content was determined by flow
cytometry using a FACScan flow cytometer (Beckton-
Dickinson, San Jose, CA, USA). Histograms were analyzed
using the Cell Quest software (Becton-Dickinson) and the
ModFit 2.0 software (Verity Software House, Topsham, Me.
USA). Respective to their phase-specific DNA-content cells
were divided into G1, S or G2/M phase or counted as
apoptotic cells.
Statistical analysis
Results of the soft agar assay and the flow cytometry
experiments were subjected to students t-test analysis to
confirm statistical significance of the data. P values of less
than 0.05 were considered as statistically significant.
Results
In order to test the cytotoxic potential of ZOL on HCT-116
colon carcinoma cells, cells were incubated with and
without a range of ZOL concentrations for 5d followed by
an MTT test to determine the cell number in each group.
Treatment of HCT-116 cells with ZOL (0–50 lM) reduced
cell growth dose dependently, with 50 lM ZOL resulting
in a more than 90% decrease in the number of viable cells
after 5 days as compared to untreated control groups
(Fig. 1). We next determined the effect of ZOL on the cell
cycle distribution of HCT 116 cells. We therefore subjected
the adherent ZOL treated cells to cell cycle analysis by PI-
staining and flow cytometry as described in material and
methods. The analysis revealed that ZOL induced an
increase of cells in the G1 Phase of the cell cycle from 79%
to 89% (P \ 0.02), indicating a G1 phase cell cycle arrest
in a population of cells (Fig. 2). In agreement with this we
observed a decrease of cells in the S Phase from 16% to 9%
(P \ 0.03) as well as a small decrease of G2 Phase cells
from 5% to 2% (P \ 0.04). Because of the pronounced
cytotoxic effect of 50 lM ZOL on cells growing on a
plastic surface we next tested if an intermediate
concentration of ZOL affects the ability of HCT-116 cells
to grow anchorage independently. We therefore subjected
HCT-116 cells to a colony forming assay in a soft agar
matrix with either 0, 12.5 or 25 lM of ZOL in the agar-
medium. Cells seeded into a soft agar layer on top of a
bottom agar layer cannot attach to any surface and there-
fore have to grow anchorage independently, which is a
hallmark of transformed and aggressively growing tumor
cells [16]. After 14d in culture, cells in the control group
formed a large number of colonies above the chosen cut-off
size while cells treated with 25 lM ZOL formed no visible
colonies at all. The number of colonies in the 12.5 lM
group was significantly (P \ 0.02) reduced as compared to
untreated cells (Fig. 3). Also the size of the colonies in the
12.5 lM ZOL group was visibly reduced as evidenced by
the pictures included in Fig. 3. We next asked if the
observed effect of ZOL on cell proliferation, cell cycle and
colony formation was accompanied by an induction of
apoptosis in the ZOL treated cells. To investigate if a
population of cells undergoes apoptosis we screened whole
protein extracts of ZOL treated HCT-116 for PARP
cleavage products by western blot analysis. Cleavage of
Poly-ADP-Ribose-Polymerase 1 (PARP) is an early and
specific indicator of apoptotic programmed cell death [17].
PARP cleavage could be detected in protein extracts of
HCT-116 cells treated with 25 and 50 lM of ZOL for 72 h,
indicating that the decrease of viable cells after ZOL
treatment was either accompanied or partly due to an
increase in tumor cell apoptosis (Fig. 4a). In order to assess
the percentage of cells that undergo apoptosis, we treated
cells with ZOL for 72 h and collected both adherent cells
and cells from the cell culture supernatant. All cells were
fixed and the percentage of apoptotic cells was determined
by measuring the DNA content in a flow cytometer. The
amount of cells with an apoptotic, sub G1-Phase DNA
content increased from a basal 7% to more than 25%
(P \ 0.001) in the group treated with 50 lM of ZOL
(Fig. 4b). To further elucidate the mechanism of this
observed induction of apoptosis we analyzed key apoptosis
related proteins by western blot with special regard to
caspase activation. To detect activated caspases, HCT-116
cells were incubated with ZOL concentrations ranging
from 1 to 50 lM for 72 h and whole cell protein extracts
subjected to SDS-PAGE followed by western blotting and
immunodetection of activated caspase cleavage products.
ZOL treatment activated caspases 3 and 7, which are
effector-caspases located at the end of the caspase cascade.
Besides activation of caspases 3 and 7 we also detected
cleavage of caspase 9 in ZOL treated HCT-116 cells,
indicating an activation of the intrinsic, mitochondrial
pathway of apoptosis induction. In addition we detected
Caspase 8 cleavage products in the ZOL treated HCT-116
cells, further supporting an activation of the mitochondrial
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Fig. 1 Zoledronic acid inhibits growth of tumor cell lines of
gastrointestinal heritage. HCT-116 were incubated with the indicated
concentrations of ZOL. After 5 days of incubation cell count was
determined by an MTT assay as described in methods. Shown is the
average of three independent experiments
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pathway. HCT-116 cells have been described as type II
apoptotic cells [18, 19], where caspase 8 activation, toge-
ther with activated caspase 9, initiates the mitochondrial
apoptosis pathway. It should mentioned that only low
concentrations of 5 lM ZOL were sufficient to activate all
the caspases mentioned above, with detectable caspase 7
activation occurring at only 1 lM (Fig. 5). To substantiate
an activation of the mitochondrial pathway of apoptosis,
we next checked whether the observed activation of casp-
ases was accompanied by a release of cytochrome c from
the mitochondria into the cytosol. During the mitochondrial
induction of apoptosis the mitochondrial membrane loses
its membrane potential and becomes permeable, which
results in a release of mitochondrial proteins into the
cytosol [20]. We therefore prepared cytosolic protein
extracts of HCT-116 cells treated with ZOL and analyzed
cytochrome c levels by western blot detection. Compared
to the untreated group, 72 h of ZOL treatment strongly
increased the amount of cytochrome c in the cytosolic
fraction of the treated cells, indicating a release from the
apoptotic mitochondria into the cytosol (Fig. 6). If ZOL
induces the mitochondrial pathway of apoptosis, there
70.0
75.0
80.0
85.0
90.0
95.0
0 µM ZOL 50 µM  ZOL%
 o
f c
el
ls
 in
 G
1 
Ph
as
e
0.0
5.0
10.0
15.0
20.0
0 µM ZOL 50 µM  ZOL
%
 o
f c
el
ls
 in
 S
 P
ha
se
0.0
2.0
4.0
6.0
8.0
0 µM ZOL 50 µM  ZOL
%
 o
f c
el
ls
 in
 G
2 
Ph
as
e
Control
50µM ZOL 72h
Fig. 2 Zoledronic acid induces
a G1 cell cycle arrest. HCT-116
cells were incubated with the
indicated concentrations of ZOL
and DNA content was analyzed
by flow cytometry. According to
DNA content cells were
allocated to the G1, S or G2
phases of the cell cycle. The
figures on the left show the
result of three independent
experiments. The histograms on
the right show an almost
complete shift of the still
adherent HCT-116 cells to the
G1 peak of the cell cycle after
treatment with 50 lM ZOL for
72 h
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Fig. 3 Zoledronic acid inhibits
anchorage independent growth
of HCT-116. In each well
20,000 (60,000 for pictures)
HCT-116 cells were seeded into
a 3D agar matrix on top of a
base agar layer in presence of 0,
12.5 and 25 lM of ZOL in both
agar layers. After 14d of
incubation the number of
colonies formed in each well
was counted under a light
microscope. The bars shown
represent the average of three
wells counted for each group.
The results were confirmed in
four independent experiments
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should be, together with the release of cytochrome c into
the cytosol, a decrease of cytosolic Bax [20]. Bax is a pro-
apoptotic member of the Bcl-2 gene family which pro-
motes apoptosis by translocation into the mitochondrial
membrane and disruption of its integrity. Cytosolic protein
extracts of ZOL treated cells were prepared and analyzed
for their Bax level by western blotting. Indeed, treatment
with 50 lM ZOL for 72 h reduced the amount of Bax
present in the cytosol. Since we observed a pronounced
activation of caspase 8, which is known to activate the
proapoptotic Bcl-2 family member Bid by cleavage, we
also analyzed the amount of full length Bid protein in
whole cell extracts. While 25 lM of ZOL somewhat
reduced the amount of uncleaved Bid protein, 50 lM of
ZOL reduced the amount of full length Bid to almost
undetectable levels (Fig. 6). In addition we analyzed the
same whole cell extracts for the expression levels of the
antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xl. As
expected Bcl-2 levels decreased substantially in the ZOL
treated groups. In contrast, Bcl-xl levels were not affected
(Fig. 6). Because previous studies have shown that ZOL
treatment of tumor cells can cause a release of apoptosis
inducing factor (AIF) from the mitochondria into the
cytosol [21], we also analyzed AIF levels in our cytosolic
protein extracts. As shown in Fig. 6, treatment of HCT-116
cells with ZOL for 72 h resulted in a release of AIF into the
cytosol.
Discussion
ZOL, although not a classic cytostatic, had a pronounced
cytotoxic effect on HCT-116 cells. Concentrations of
25 lM and 50 lM strongly inhibited cell proliferation and
decreased the number of viable cells after 5 days of treat-
ment by over 90%. This dramatic reduction in tumor cell
number can be caused by a slowing of cell proliferation as
well as by an induction of apoptosis. Cell cycle analysis of
the ZOL treated cells that had not yet detached from the
cell culture surface revealed that a population of ZOL
treated HCT-116 cells undergoes a G1 cell cycle arrest
which suggests an impairment of cell cycle progression and
a decrease of cell proliferation. ZOL acts as an inhibitor of
the mevalonate pathway, ultimately preventing the pre-
nylation of small GTPases such as Ras, Rho or Rac [3].
Inhibition of Ras mediated growth factor signalling can
stall the progression through the cell cycle of a variety of
tumor cell lines [22]. In agreement with this we found an
inhibition of proliferation in ZOL treated HCT-116 cells.
Since ZOL has been shown to decrease cell proliferation of
lung cancer cells without any detectable induction of apop-
tosis [23], we needed to check if HCT-116 cells undergo
apoptosis in addition to the slowing of cell proliferation. The
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Fig. 4 Zoledronic acid induces apoptosis. (a) HCT-116 cells were
incubated with ZOL for 72 h followed by western blot analysis of
Poly-ADP-Ribose-Polymerase 1 (PARP) cleavage products. The
amount of beta-actin protein served as loading control. (b) HCT-
116 cells were incubated with the indicated concentrations of ZOL
and DNA content was analyzed by flow cytometry. Cells with a sub
G1 Phase DNA content were counted as apoptotic cells. The bars
represent one representative experiment in triplicates
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Fig. 5 Zoledronic acid induces activation of caspases 3, 7, 8 and 9 in
HCT-116 cells. HCT-116 cells were incubated with ZOL for 72 h and
whole protein extracts were subjected to western analysis of activated
caspase cleavage products. Beta-actin 43 kDa protein detection was
used as control. All antibodies used detect full length procaspases as
well as activated cleavage products. The bands above the caspase
cleavage products are the uncleaved procaspases
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cleavage of PARP in ZOL treated HCT-116 cells clearly
shows an induction of apoptosis. This was further confirmed
by flow cytometric detection of apoptotic cells characterized
by a sub G1 DNA content, which increased from 7% to 25%.
It is interesting to note that virtually all apoptotic cells had
detached from the cell culture surface before undergoing
apoptosis. The cell cycle analysis of the adherent cells
revealed a G1 arrest but failed to detect any apoptotic cells.
Only when the detached cells in the supernatant were har-
vested together with the adherent cells we detected a large
percentage of apoptotic cells in the ZOL treated groups. This
suggests that ZOL caused the detachment of HCT-116 cells
with a subsequent induction of apoptosis. Since ZOL disrupts
the prenylation of small GTPases, it is conceivable that an
impaired function of Rho family GTPases caused the
detachment of the HCT-116 cells via a disruption of cyto-
skeletal integrity. Indeed, ZOL has been shown to target the
cytoskeleton of cells in a number of studies [24–26]. A recent
study investigated the effect of a hexane extract from the
plant Chios mastic gum on HCT-116 cells and observed a G1
arrest of the cells, followed by detachment and subsequent
apoptosis [27]. Our data indicates that ZOL exerts a similar
effect on HCT-116 cells.
Independent of the sequence of events we were able to
show that ZOL induced apoptosis is caspase dependent,
with detectable activation of caspases even at low con-
centrations of only 1–5 lM ZOL. Furthermore we were
able to show that this induction of apoptosis includes the
intrinsic, mitochondrial pathway, which is characterized by
a translocation of Bax from the cytosol into the mito-
chondrial membrane thereby disrupting membrane
integrity. Bax, a proapoptotic member of the Bcl-2 family
exerts its effect by oligomerizing and thus contributing to
permeabilisation of the mitochondrial outer membrane [28,
29]. This leads to a release of cytochrome c into the cytosol
where it triggers a number of apoptotic events, including
the activation of caspase 9 which in turn activates caspase 3
and caspase 7 [30]. In addition we observed a pronounced
activation of the initiator caspase 8 starting at 5 lM of
ZOL. Although caspase 8 activation is generally associated
with the death receptor mediated, extrinsic pathway of
apoptosis its activation is commonly observed in cells
treated with cytotoxic agents. Treatment of HCT-116 cells
with the diterpene sclareol as well as exposure of HCT-116
cells to the cytotoxic agent WMC-79 resulted in an acti-
vation of the initiator caspase 8 together with caspase 9
[31, 32]. In line with this result is the observed reduction of
full length Bid protein in cell extracts from cells treated
with 25 and 50 lM ZOL. The proapoptotic Bcl-2 family
protein Bid is cleaved and activated by caspase 8 and
subsequently associates with proapoptotic Bax to disrupt
mitochondrial integrity [33]. Together with this activation
of Bid and Bax we found a decrease of overall Bcl-2
expression in whole cell extracts treated with 25 and
50 lM of ZOL. This is in agreement with previous studies
describing a downregulation of Bcl-2 in apoptotic HCT-
116 cells treated with cytotoxic agents [32]. Unexpectedly
and in contrast to Bcl-2, Bcl-xl levels remained unaffected
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Fig. 6 Zoledronic acid
activates the mitochondrial
pathway of apotosis in HCT-
116 cells. Cells were incubated
with ZOL for 72 h, followed by
preparation of cytosolic protein
extracts and western analysis of
cytochrome C, Bax and AIF as
indicated by the arrows. Whole
cell extracts were used for the
detection of Bid, Bcl-2 and Bcl-
xl proteins. 43 kDa beta-actin
was used as loading control for
each sample
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by treatment with ZOL. In spite of intact Bcl-xl levels our
data suggests a ZOL induced activation of the mitochon-
drial pathway of apoptosis, including Caspase 8 mediated
Bid activation, Bax translocation, cytochrome c release and
finally an activation of the executioner caspases 3 and 7. In
addition we detected an increase of AIF in the cytosolic
fraction of ZOL treated HCT-116 cells, which is a key
trigger of caspase independent apoptosis [34, 35]. It
remains unclear whether ZOL causes apoptosis via a solely
caspase dependent mechanism or if the AIF induced
pathway is also involved. Our data shows that ZOL acti-
vates the intrinsic pathway of apoptosis induction via the
mitochondrial pathway with a concurrent release of AIF
into the cytosol. Because AIF is a key trigger of caspase
independent apoptosis [35], we speculate that ZOL induces
apoptotic cell death of HCT-116 cells in a caspase
dependent and in a caspase independent mechanism. We
furthermore demonstrated that HCT-116 cells treated with
25 lM of ZOL completely lose their ability for anchorage
independent growth in a soft agar matrix while 12.5 lM
severely reduce the number and size of the colonies. The
ability to grow in soft agar is an indicator for the invasive
potential of a tumor cell line [16]. Aggressively metasta-
sizing tumor cells can invade through basement
membranes and grow in the absence of anchorage to their
native matrix environment to finally establish tumors in
other tissues. The pronounced effect of ZOL in the soft
agar assay indicates an inhibition of the invasive potential
of HCT-116 colon carcinoma cells. Taken together, our
data shows that ZOL has potent cytotoxic activity on HCT-
116 colon carcinoma cells even at low micromolar con-
centrations. Whether these findings can be used for the
treatment of primary colon carcinoma or visceral metas-
tases will need to be further studied. The nitrogen
containing bisphosphonate minodronate has been shown to
inhibit the growth of subcutaneous melanoma xenografts
almost completely and thus significantly prolonged sur-
vival of the xenografted mice [13]. This leaves room to
speculate that the related compound ZOL could potentially
have the same potent action on primary tumors. ZOL itself
effectively prevented the formation of lung metastases in
an in vivo model, where osteosarcoma cells were injected
intravenously into mice. In that study ZOL completely
prevented the formation of lung metastasis and prolonged
overall survival of the mice [36]. Another interesting
thought is that although ZOL itself is not administered
orally other bisphosphonates are routinely prescribed in
tablet form for the treatment of osteoporosis. Since all
bisphosphonates have a very limited intestinal absorption
rate of only 1 to maximally 10% [37], there is a large
fraction of the drug present in the colon. Taking into
account the potent antitumoral effect of ZOL on a colon
carcinoma cell line one could speculate that other, orally
administered bisphosphonates have a chemopreventive
effect on the development of colon carcinomas.
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